Literature DB >> 18590949

Surgery for melanoma metastases of the gastrointestinal tract: indications and results.

A Sanki1, R A Scolyer, J F Thompson.   

Abstract

AIM: To assess survival, morbidity and mortality following therapeutic or palliative resection of gastrointestinal (GI) tract melanoma metastases.
METHODS: A retrospective case series of 117 patients who underwent surgical resection of GI melanoma metastases between 1981 and 2005 was reviewed.
RESULTS: The 117 patients underwent 142 operations for acute and/or sub-acute symptoms or for imminently symptomatic GI metastases detected radiologically. The intent of the surgery was palliative in 53 (37.3%) and therapeutic in 89 (62.7%) operations. The most common symptoms were due to anaemia (40.8%) or bowel obstruction (32.4%). The most frequently performed operation was small bowel resection (76.8%). Preoperative imaging and/or endoscopy were used in 83 cases, with computerised tomography (CT) being most frequent (85.5%). CT had a sensitivity of 68.8% when used alone to detect the presence of GI metastases in the study population. The mortality rate following GI resection was 1.4%, and 2.5% of patients had post-operative complications. Overall 5-year survival was 27%. On multivariate analysis, the presence of residual intraabdominal disease and the presence of non-GI metastases at the time of surgery or after surgery were the most significant prognostic indicators of survival.
CONCLUSIONS: Resection of GI melanoma metastases is safe, relieves symptoms and can achieve prolonged remission. In patients with limited disease, an aggressive surgical approach to symptomatic or imminently symptomatic GI melanoma metastases is warranted.

Entities:  

Mesh:

Year:  2008        PMID: 18590949     DOI: 10.1016/j.ejso.2008.04.011

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  23 in total

1.  Primary gastric melanoma: a diagnostic challenge.

Authors:  Riti Aggarwal; Shashi Dhawan; Prem Chopra
Journal:  J Gastrointest Cancer       Date:  2014-12

Review 2.  Capsule endoscopy for management of small bowel melanoma-is it time yet?

Authors:  Emilia Prakoso; Warwick S Selby
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-10

3.  Plasma markers for identifying patients with metastatic melanoma.

Authors:  Harriet M Kluger; Kathleen Hoyt; Antonella Bacchiocchi; Tina Mayer; Jonathan Kirsch; Yuval Kluger; Mario Sznol; Stephan Ariyan; Annette Molinaro; Ruth Halaban
Journal:  Clin Cancer Res       Date:  2011-04-12       Impact factor: 12.531

4.  Small Bowel Metastases: Tumor Markers for Diagnosis and Role of Surgical Palliation.

Authors:  Santosh Shenoy
Journal:  J Gastrointest Cancer       Date:  2016-06

5.  Liver resection and ablation for metastatic melanoma: A single center experience.

Authors:  Alexandre Doussot; Charlée Nardin; Haruyuki Takaki; Tess D Litchman; Michael I D'Angelica; William R Jarnagin; Michael A Postow; Joseph P Erinjeri; T Peter Kingham
Journal:  J Surg Oncol       Date:  2015-06-12       Impact factor: 3.454

6.  Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen.

Authors:  Ahmed E Othman; Thomas K Eigentler; Georg Bier; Christina Pfannenberg; Hans Bösmüller; Christian Thiel; Claus Garbe; Konstantin Nikolaou; Bernhard Klumpp
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

Review 7.  Optimal management of metastatic melanoma: current strategies and future directions.

Authors:  Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

8.  Surgical management of intraabdominal metastases from melanoma: role of the neutrophil to lymphocyte ratio as a potential prognostic factor.

Authors:  Ferdinando C M Cananzi; Angus Dalgleish; Satvinder Mudan
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

Review 9.  [Malignant head and neck melanoma: Part 2: Therapy].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-08       Impact factor: 1.284

10.  Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.

Authors:  Ferdinando C M Cananzi; Satvinder Mudan; Mary Dunne; Nneka Belonwu; Angus G Dalgleish
Journal:  Hum Vaccin Immunother       Date:  2013-07-09       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.